The estimated Net Worth of Steven A Shallcross is at least $1.21 Million dollars as of 10 May 2021. Mr. Shallcross owns over 50,000 units of Theriva Biologics Inc stock worth over $102,000 and over the last 18 years he sold SYN stock worth over $0. In addition, he makes $1,108,610 as Chief Executive Officer, Chief Financial Officer und Director at Theriva Biologics Inc.
Sign up
Mr. Shallcross SYN stock SEC Form 4 insiders trading
Steven has made over 14 trades of the Theriva Biologics Inc stock since 2006, according to the Form 4 filled with the SEC. Most recently he bought 50,000 units of SYN stock worth $24,500 on 10 May 2021.
The largest trade he's ever made was buying 50,000 units of Theriva Biologics Inc stock on 10 May 2021 worth over $24,500. On average, Steven trades about 5,225 units every 188 days since 2006. As of 10 May 2021 he still owns at least 100,000 units of Theriva Biologics Inc stock.
You can see the complete history of Mr. Shallcross stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Steven Shallcross biography
Steven A. Shallcross serves as Chief Executive Officer, Chief Financial Officer, Director of the Company. Mr. Shallcross has been a member of our Board of Directors since December 6, 2018 and currently serves as our Chief Executive Officer, a position he was appointed to on December 6, 2018, and our Chief Financial Officer. Mr. Shallcross was appointed as our Interim Chief Executive Officer on December 5, 2017 and has served as our Chief Financial Officer, Treasurer and Secretary since joining us in June 2015. Mr. Shallcross brings to our company operational, financial and international biotech industry experience, as well as an established track record at leading the financial development and strategy for several publicly traded biotech companies. From May 2013 through May 2015, Mr. Shallcross served as Executive Vice President and Chief Financial Officer of Nuo Therapeutics, Inc. (formerly Cytomedix, Inc.). In January 2016, Nuo Therapeutics, Inc. filed a voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware and on April 25, 2016, the Bankruptcy Court entered an order granting approval of Nuo’s plan of reorganization. From July 2012 to May 2013, Mr. Shallcross held the offices of Executive Vice President, Chief Financial Officer and Treasurer of Empire Petroleum Partners, LLC, a motor fuel distribution company. From July 2011 to March 2012, Mr. Shallcross was Acting Chief Financial Officer of Senseonics, a privately-held medical device company located in Germantown, MD. From January 2009 to March 2011, he served as Executive Vice President and Chief Financial Officer of Innocoll AG (formerly privately held Innocoll Holdings, Inc.), a global, commercial-stage biopharmaceutical company specializing in the development and commercialization of collagen-based products.
What is the salary of Steven Shallcross?
As the Chief Executive Officer, Chief Financial Officer und Director of Theriva Biologics Inc, the total compensation of Steven Shallcross at Theriva Biologics Inc is $1,108,610. There are no executives at Theriva Biologics Inc getting paid more.
How old is Steven Shallcross?
Steven Shallcross is 58, he's been the Chief Executive Officer, Chief Financial Officer und Director of Theriva Biologics Inc since 2018. There are 2 older and 2 younger executives at Theriva Biologics Inc. The oldest executive at Theriva Biologics Inc is John Monahan, 73, who is the Director.
What's Steven Shallcross's mailing address?
Steven's mailing address filed with the SEC is C/O SYNTHETIC BIOLOGICS, INC.,, 9605 MEDICAL CENTER DRIVE, SUITE 270, ROCKVILLE, MD, 20850.
Insiders trading at Theriva Biologics Inc
Over the last 13 years, insiders at Theriva Biologics Inc have traded over $8,016,723 worth of Theriva Biologics Inc stock and bought 6,682,900 units worth $10,572,593 . The most active insiders traders include Randal Jintrexon Corp Kirk, Steve H Kanzer und Scott Tarriff. On average, Theriva Biologics Inc executives and independent directors trade stock every 223 days with the average trade being worth of $899,000. The most recent stock trade was executed by Steven A Shallcross on 10 May 2021, trading 50,000 units of SYN stock currently worth $24,500.
What does Theriva Biologics Inc do?
Synthetic Biologics, Inc. is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The Company's lead candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR), and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.
What does Theriva Biologics Inc's logo look like?
Complete history of Mr. Shallcross stock trades at Vanda Pharmaceuticals Inc, Theriva Biologics Inc und Newgioco
Theriva Biologics Inc executives and stock owners
Theriva Biologics Inc executives and other stock owners filed with the SEC include:
-
Steven Shallcross,
Chief Executive Officer, Chief Financial Officer, Director -
Steven A. Shallcross CPA,
CEO, CFO, Treasurer, Corp. Sec. & Director -
Jeffrey Kraws,
Non-Executive Independent Chairman of the Board -
John Monahan,
Director -
Jeffrey Wolf,
Independent Director -
Dr. Frank Tufaro Ph.D.,
Chief Operating Officer -
Lara M. Guzman,
Sr. Director of Project Operations -
Dr. Michael Kaleko,
Sr. VP of R&D -
Dr. Vince Wacher,
Head of Product and Corp. Devel. -
Vincent I. Perrone,
Director of Corp. Communication -
Jeffrey Scott Riley,
CEO and President -
Randal Jintrexon Corp Kirk,
-
Joseph A. Sliman,
Chief Medical Officer -
Steve H Kanzer,
10% owner -
Charles Evan Ballantyne,
Chief Financial Officer -
Scott Tarriff,